Ovid Therapeutics (OVID) Free Cash Flow (2016 - 2026)
Ovid Therapeutics (OVID) posted Free Cash Flow of -$13.9 million for Q1 2026, down 33.98% on a QoQ basis from -$10.4 million in Q4 2025, and down 35.2% year-over-year from -$21.5 million in Q1 2025.
Ovid Therapeutics (OVID) Free Cash Flow (2016 - 2026) Analysis & Trends
Ovid Therapeutics' Free Cash Flow history runs 11 years deep, the most recent figure standing at -$13.9 million for Q1 2026.
- Quarterly Free Cash Flow fell 35.2% year-over-year to -$13.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$41.9 million (up 15.52% YoY) and the FY2025 annual result came in at -$38.3 million, up 31.66% from the prior year.
- Free Cash Flow was -$13.9 million for Q1 2026 at Ovid Therapeutics, down from -$10.4 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$4.8 million in Q2 2025 and bottomed at -$20.1 million in Q1 2022.
- A 5-year average of -$12.4 million and a median of -$12.1 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow plunged 112.5% — and 2025, when it jumped 66.42%.
- Ovid Therapeutics' Free Cash Flow stood at -$9.3 million in 2022, then fell by 28.89% to -$12.0 million in 2023, then advanced by 16.68% to -$10.0 million in 2024, then dropped by 3.93% to -$10.4 million in 2025, then sank by 33.98% to -$13.9 million in 2026.
- Business Quant data shows OVID's Free Cash Flow at -$13.9 million in Q1 2026, -$10.4 million in Q4 2025, and -$12.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Ovid Therapeutics | 120.41 Mn | -35.11 Mn | - | -13.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.90 Mn |
| Mar 31, 2026 | -13.90 Mn |
| Dec 31, 2025 | -10.37 Mn |
| Dec 31, 2025 | -10.37 Mn |
| Sep 30, 2025 | -12.83 Mn |
| Sep 30, 2025 | -12.83 Mn |
| Jun 30, 2025 | -4.82 Mn |
| Jun 30, 2025 | -4.82 Mn |
| Mar 31, 2025 | -10.28 Mn |
| Mar 31, 2025 | -10.28 Mn |
| Dec 31, 2024 | -9.98 Mn |
| Dec 31, 2024 | -9.98 Mn |
| Sep 30, 2024 | -15.01 Mn |
| Sep 30, 2024 | -15.01 Mn |
| Jun 30, 2024 | -14.35 Mn |
| Jun 30, 2024 | -14.35 Mn |
| Mar 31, 2024 | -16.71 Mn |
| Mar 31, 2024 | -16.71 Mn |
| Dec 31, 2023 | -11.98 Mn |
| Dec 31, 2023 | -11.98 Mn |